Blueprint

R&D Blueprint

The R&D Blueprint is a global strategy and preparedness plan that allows the rapid activation of research and development activities during epidemics. Its aim is to fast-track the availability of effective tests, vaccines and medicines that can be used to save lives and avert large scale crises.

Key actions by disease

A scientist woman pulling out a tube from a freezer for genetic testing

Prioritizing diseases for research and development in emergency contexts

COVID-19

Ebolavirus and Marburg

Lassa Fever

MERS-CoV & SARS

Mpox (monkeypox)

Nipah & Henipaviruses

Plague

Zika Virus

Upcoming consultations

29 – 30 August 2024

Mpox research and innovation - aligning research response with outbreak goals

19 January 2024 13:00 – 18:00 CET

Research response to pathogen X during a pandemic

18 January 2024 13:00 – 18:00 CET

Critical research for priority pathogens with epidemic potential

9 January 2024

A scientific framework for epidemic and pandemic research preparedness

23 – 24 October 2023

Global Research and Innovations Forum: Building the world’s resilience against future outbreaks and pandemics

R&D Blueprint calendar of upcoming events

28 March 2023

Useful resources

About R&D Blueprint

Accelerating R&D and Saving Lives

Download

A technician prepares a microscopic slide in a laboratory

Research and Development (R&D) Roadmaps

Heath providers vaccinating children in a community

Good Participatory Practice

Related activities

Online learning

All →

7 June 2023

Clinical trials for new/re-emerging pathogens: GPP -- Module 1: Welcome, Importance by Nina Gobat

Infographics

All →

1 June 2022

Estudio Solidaridad de Vacunas (ESV)

1 June 2022

Vaccins de l’essai Solidarity (STV)

22 December 2021

COVID-19 vaccines research: WHO consultation on omicron variant immunity

Documents

All →

The tab is the result of a preliminary landscape of therapeutics licensed or under development for Mpox

Download

The tab is the result of a preliminary landscape of vaccines licensed or under development for Mpox

Download

This document provides a list of Paramyxovirus vaccines and therapeutics licensed or under development for pathogens being considered as PRIORITY PATHOGENS.

Download

This document provides a list of vaccines and therapeutics licensed or under development for pathogens being considered as PRIORITY PATHOGENS.

Download

Publications

All →

This large, international, randomized controlled clinical trial is designed to enable an expeditious, agile and concurrent evaluation of the benefits and...

Download

There has been some suggestions for the inclusion of Favipiravir in the Solidarity trial.

Download

Currently, there are no licensed vaccines for the prevention of COVID 19. While efforts continue to develop effective vaccines, it is pertinent to examine...

Download